Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy E Davidson

Showing results (241-250 of 285) with videos related to

Pageof 29
Sort By:
JAMA Oncology|December 8, 2016
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain MetastasesNolan Priedigkeit, Ryan J Hartmaier, Yijing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guidelineSharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
The Oncologist|June 2, 2021
Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer CentersKristen K McNiff, Michael A Caligiuri, Nancy E Davidson, et al.
NPJ Breast Cancer|May 17, 2023
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancerYuli Chen, Haojia Li, Andrew Janowczyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerHarold J Burstein, Ann Alexis Prestrud, Jerome Seidenfeld, et al.
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
JAMA Oncology|January 10, 2020
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast CancerWendy A Woodward, William E Barlow, Reshma Jagsi, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Pageof 29

Showing results (241-250 of 285) with videos related to

Sort By:
Pageof 29
JAMA Oncology|December 8, 2016
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain MetastasesNolan Priedigkeit, Ryan J Hartmaier, Yijing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guidelineSharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
The Oncologist|June 2, 2021
Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer CentersKristen K McNiff, Michael A Caligiuri, Nancy E Davidson, et al.
NPJ Breast Cancer|May 17, 2023
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancerYuli Chen, Haojia Li, Andrew Janowczyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerHarold J Burstein, Ann Alexis Prestrud, Jerome Seidenfeld, et al.
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
JAMA Oncology|January 10, 2020
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast CancerWendy A Woodward, William E Barlow, Reshma Jagsi, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Pageof 29